Minsheng Securities released a research report on April 26 stating that it gave Jiangsu Wu Zhong (600200.SH) a careful recommendation rating. The main reasons for the rating include: 1) the pharmaceutical business contributes the main revenue, and the growth of the medical and aesthetic business is worth looking forward to; 2) AestheFill polylactic acid facial fillers were approved for sale, focusing on the progress of the promotion of recycled materials; 3) focusing on high-end injectable medical and aesthetic products to enrich the product pipeline. (Mainichi Keizai Shimbun)
民生证券4月26日发布研报称，给予江苏吴中（600200.SH）谨慎推荐评级。评级理由主要包括：1）医药业务贡献主要营收，医美业务增长值得期待；2）AestheFill艾塑菲聚乳酸面部填充剂获批上市，关注再生材料推广进展；3）聚焦高端注射类医美产品，丰富产品管线。（每日经济新闻）
Minsheng Securities released a research report on April 26 stating that it gave Jiangsu Wu Zhong (600200.SH) a careful recommendation rating. The main reasons for the rating include: 1) the pharmaceutical business contributes the main revenue, and the gro
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated